The biopharmaceutical industry focuses on the development of therapies derived from biological sources. These companies create products that treat cancers, genetic disorders, and infectious diseases, often using advanced techniques like monoclonal antibodies and gene therapies. The sector is rapidly evolving, with innovations driven by cutting-edge research. Additionally, the industry's commitment to improving healthcare access is reshaping market demand. By prioritizing patient outcomes and effective treatments, biopharmaceutical companies are setting the stage for a more proactive approach to disease management and preventive care in the future.

This list highlights 26 biopharmaceutical companies of varying sizes specializing in innovative therapies and products. Spanning locales from the United States to Europe and Asia, these firms were established between 1941 and 2020. Businesses like Seattle Genetics and Octapharma have made notable contributions in oncology and plasma-derived therapies. With employee counts ranging from under 50 to above 10,000, each company reflects the distinct expertise required to tackle specific healthcare needs.

Explore the highlights of top biopharmaceutical companies.

Top 26 Biopharmaceutical Companies Companies

1. Seattle Genetics

• Website: seattlegenetics.com
• Ownership type: Private
• Headquarters: Bothell, Washington, United States (USA)
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn: seattle-genetics

Seattle Genetics, based in Bothell, Washington, is a biopharmaceutical company founded in 1998. The company is dedicated to developing and manufacturing innovative therapies for cancer treatment, particularly through its pioneering work in antibody-drug conjugates (ADCs). Seattle Genetics is known for its flagship product, Adcetris, which has been approved for the treatment of certain types of lymphoma. The company continues to expand its product pipeline, focusing on targeted therapies that aim to improve patient outcomes while reducing side effects. With a workforce of over 2,000 employees, Seattle Genetics is actively involved in clinical trials and research initiatives to bring new therapies to market, demonstrating its commitment to advancing cancer treatment.

2. Octapharma

• Website: octapharma.com
• Ownership type: Private
• Headquarters: Lachen, Schwyz, Switzerland
• Employee distribution: Austria 24%, United States (USA) 23%, Sweden 15%, Other 38%
• Founded year: 1983
• Headcount: 10001+
• LinkedIn: octapharma

Octapharma AG, founded in 1983 and headquartered in Lachen, Switzerland, is a prominent private pharmaceutical company specializing in the development and production of human proteins derived from plasma and cell lines. The company operates in three main therapeutic areas: haematology, immunotherapy, and critical care. Octapharma is recognized as the largest privately owned plasma fractionator globally, with a network of plasma donation centers and manufacturing sites across multiple countries. Their products are essential for treating rare diseases, bleeding disorders, and critical care situations, impacting the lives of patients worldwide. The company emphasizes quality and safety throughout its production processes, ensuring that their therapies meet rigorous standards. With a workforce of over 10,000 employees and a commitment to research and development, Octapharma continues to innovate and expand its product offerings, making it a significant player in the biopharmaceutical industry.

3. Eisai Co., Ltd.

• Website: eisai.com
• Ownership type: Private
• Headquarters: Bunkyo City, Tokyo, Japan
• Employee distribution: Japan 54%, Vietnam 8%, United States (USA) 6%, Other 32%
• Founded year: 1941
• Headcount: 1001-5000
• LinkedIn: %e3%82%a8%e3%83%bc%e3%82%b6%e3%82%a4%ef%bc%88%e6%a0%aa%ef%bc%89

Eisai Co., Ltd., founded in 1941 and based in Bunkyo City, Tokyo, Japan, is a pharmaceutical company dedicated to drug discovery and development. The company specializes in creating innovative treatments primarily in the fields of oncology and neurology. Eisai's mission is to enhance patient outcomes and improve access to medicines, which they pursue through extensive research and development efforts. With a workforce of over 600 employees, the company operates globally, with significant presence in Japan, Vietnam, the United States, and other countries. Eisai is also engaged in various initiatives aimed at improving access to medicines, particularly in developing regions, showcasing their commitment to global health. Their recent advancements in clinical trials and product approvals, such as the treatment for Alzheimer’s disease, highlight their active role in the biopharmaceutical industry.

4. Samsung Bioepis

• Website: samsungbioepis.com
• Ownership type: Corporate
• Headquarters: Yeonsu-Gu, Incheon, South Korea
• Employee distribution: South Korea 91%, Netherlands 3%, Other 6%
• Latest funding: January 2022
• Founded year: 2012
• Headcount: 501-1000
• LinkedIn: samsungbioepis

Samsung Bioepis, based in Yeonsu-Gu, Incheon, South Korea, is a biopharmaceutical company focused on the development and commercialization of biosimilar medicines. Established in 2012, the company aims to improve patient access to high-quality biologic therapies. Their product portfolio includes biosimilars for key therapeutic areas such as immunology and oncology, with notable approvals for drugs like trastuzumab and adalimumab. Samsung Bioepis collaborates with partners like Biogen and Organon to ensure the global availability of its products. The company is also expanding its pipeline to include treatments for ophthalmology, gastroenterology, and hematology, reflecting its commitment to innovation and addressing patient needs. With a workforce of around 1,000 employees, Samsung Bioepis is dedicated to transforming the way biologic therapies are developed and delivered to patients.

5. PROBIOMED S.A. de C.V.

• Website: probiomed.com.mx
• Ownership type: Corporate
• Headquarters: Mexico
• Employee distribution: Mexico 99%
• Latest funding: May 2022
• Founded year: 1970
• Headcount: 501-1000
• LinkedIn: probiomedmx

PROBIOMED S.A. de C.V. is a Mexican biopharmaceutical company founded in 1970, dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products for human health. With a workforce of approximately 657 employees, the company operates primarily in Mexico, contributing significantly to the local healthcare landscape. PROBIOMED focuses on creating high-tech biopharmaceutical products that enhance patient access to effective treatments. Their portfolio includes a wide range of therapies targeting serious diseases such as cancer, chronic kidney disease, rheumatoid arthritis, multiple sclerosis, and diabetes. The company also produces generic drugs and biocomparables, including cytokines, monoclonal antibodies, fusion proteins, and recombinant vaccines. This extensive product range positions PROBIOMED as a key player in the biopharmaceutical sector, committed to improving health outcomes for patients both in Mexico and globally.

6. Bharat Biotech

• Website: bharatbiotech.com
• Ownership type: Venture Capital
• Headquarters: Hyderabad, Telangana, India
• Employee distribution: India 99%
• Latest funding: Other (Grant), $14.1M, June 2020
• Founded year: 1996
• Headcount: 1001-5000
• LinkedIn: bharat-biotechil

Bharat Biotech International Limited, based in Hyderabad, India, is a biotechnology company that specializes in the development and manufacturing of vaccines and biotherapeutics. Established in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra Ella, the company has made significant strides in addressing infectious diseases, particularly in developing nations. With a workforce of approximately 1,800 employees, Bharat Biotech has developed a portfolio of vaccines that includes COVAXIN, India's first indigenous COVID-19 vaccine, and other notable products like ROTAVAC and Typbar TCV. The company has a strong emphasis on research and development, holding over 220 patents and maintaining manufacturing facilities approved by global health authorities such as the USFDA and WHO. Bharat Biotech's mission is to deliver affordable and high-quality healthcare solutions, and it has successfully supplied over 9 billion vaccine doses worldwide, demonstrating its impact on global health.

7. Dendreon

• Website: dendreon.com
• Ownership type: Corporate
• Headquarters: Seal Beach, California, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Latest funding: $819.9M, June 2017
• Founded year: 1992
• Headcount: 501-1000
• LinkedIn: dendreon

Dendreon Pharmaceuticals LLC, based in Seal Beach, California, is a biotechnology company focused on immunotherapy for cancer treatment. Founded in 1992, Dendreon has made significant strides in the biopharmaceutical industry with its flagship product, Provenge (sipuleucel-T), which is an FDA-approved treatment for advanced prostate cancer. This innovative therapy harnesses the power of the patient's own immune cells to detect and attack cancer cells, marking a significant advancement in personalized medicine. Since its approval in 2010, Provenge has been administered to nearly 40,000 men, demonstrating its impact on patient outcomes. In addition to its therapeutic offerings, Dendreon provides cellular therapy manufacturing services, aiding other companies in the development and commercialization of novel cancer therapies. This dual focus on both treatment and manufacturing positions Dendreon as a key player in the biopharmaceutical landscape, committed to improving patient lives through innovative science and cellular therapies.

8. Chi-Med (Hutchison China MediTech)

• Website: chi-med.com
• Ownership type: Private
• Headquarters: Hong Kong S.A.R
• Founded year: 2000
• Headcount: 5001-10000
• LinkedIn: hchimed

Chi-Med (Hutchison China MediTech) is a biopharmaceutical company based in Hong Kong, founded in 2000. The company specializes in the discovery, development, and commercialization of targeted therapies and immunotherapies aimed at treating cancer and autoimmune diseases. Chi-Med is dedicated to addressing unmet medical needs through innovative drug development, primarily focusing on therapies that can significantly improve patient outcomes. The company has a robust pipeline, with several candidates in clinical trials, including surufatinib, which has shown promise in treating neuroendocrine tumors. Chi-Med operates with a strong commitment to research and development, employing a team of approximately 470 professionals in this area. Their commercial platform is well-established in China, allowing them to effectively market and distribute their products across a wide network of healthcare providers. Chi-Med is publicly traded on the Nasdaq and the London Stock Exchange, reflecting its stature in the biopharmaceutical industry.

9. Kedrion Biopharma

• Website: kedrion.com
• Ownership type: Private Equity
• Headquarters: Fort Lee, New Jersey, United States (USA)
• Employee distribution: Italy 49%, United States (USA) 27%, United Kingdom (UK) 14%, Other 11%
• Latest funding: September 2022
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn: kedrion-biopharma

Kedrion Biopharma is a biopharmaceutical company founded in 2001, headquartered in Fort Lee, New Jersey. The company specializes in the collection and fractionation of blood plasma to produce and distribute plasma-derived therapies aimed at treating rare and debilitating conditions, such as coagulation and neurological disorders, as well as immunodeficiencies. Kedrion operates on a global scale, with production plants in several countries and a network of plasma collection centers in the United States and the Czech Republic. The company has made significant strides in the industry, including its acquisition of Bio Products Laboratory in 2022, which enhances its capabilities in providing high-quality plasma-derived medicines. Kedrion is committed to maintaining high industry standards and aims to support national health systems in achieving self-sufficiency in plasma-derived products through technology transfer and collaboration.

10. NPS Pharma

• Website: shire.com
• Ownership type: Corporate
• Headquarters: Bedminster, New Jersey, United States (USA)
• Employee distribution: United States (USA) 51%, Algeria 12%, Ireland 12%, Other 25%
• Latest funding: $86.4B, April 2018
• Founded year: 1986
• Headcount: 201-500
• LinkedIn: nps-pharmaceuticals

NPS Pharma, a subsidiary of Takeda Pharmaceutical Company Limited, is based in Bedminster, New Jersey. Founded in 1986, the company specializes in the research, development, manufacturing, and marketing of innovative medicines. NPS Pharma focuses on therapeutic areas such as gastrointestinal diseases, rare diseases, oncology, and vaccines. Their mission is to transform the lives of patients by providing treatments for conditions that often have limited or no existing options. The company has a strong commitment to advancing science and technology in healthcare, which is reflected in their robust pipeline of products and ongoing clinical trials. NPS Pharma's dedication to addressing unmet medical needs positions it as a significant contributor to the biopharmaceutical industry.

11. Aimmune Therapeutics

• Website: aimmune.com
• Ownership type: Corporate
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 81%, United Kingdom (UK) 10%, Switzerland 5%, Other 4%
• Latest funding: $2.6B, August 2020
• Founded year: 2011
• Headcount: 501-1000
• LinkedIn: aimmune-therapeutics

Aimmune Therapeutics, based in Brisbane, California, is a biopharmaceutical company founded in 2011. The company is dedicated to developing innovative therapies aimed at treating food allergies and related gastrointestinal and metabolic diseases. Aimmune's mission is to transform the lives of patients and their families by providing effective, science-driven treatments that help manage these conditions. The company collaborates with prominent biotechnology firms to enhance its research and development efforts. Aimmune operates within the healthcare sector and has garnered significant funding, amounting to $2.6 billion as of August 2020, reflecting strong investor interest in its specialized focus. As a subsidiary of Nestlé Health Science, Aimmune benefits from additional resources and expertise, further solidifying its position in the biopharmaceutical industry.

12. Amgen Deutschland

• Website: amgen.de
• Ownership type: Private
• Headquarters: Munich, Bavaria, Germany
• Employee distribution: Germany 97%, Jordan 3%
• Founded year: 1989
• Headcount: 501-1000
• LinkedIn: amgengermany

Amgen Deutschland, based in Munich, Bavaria, is a biotechnology company that has been operational since 1989. The company focuses on developing innovative therapies for serious diseases, with a strong emphasis on oncology and chronic inflammatory conditions. Amgen Deutschland offers a range of biopharmaceutical products and biosimilars, demonstrating a commitment to advancing medical solutions that enhance patient outcomes. Their research efforts are directed towards understanding biological mechanisms of diseases and the biotechnological manufacturing of medicines. The company also engages in educational initiatives, such as the Amgen Biotech Experience and the Amgen Scholars Europe Program, which aim to inspire and educate future scientists. Through partnerships and community involvement, Amgen Deutschland seeks to foster a deeper understanding of biotechnology and its applications in healthcare.

13. Sunovion Pharmaceuticals

• Website: sunovion.com
• Ownership type: Corporate
• Headquarters: Marlborough, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Latest funding: $2.6B, September 2009
• Founded year: 2010
• Headcount: 501-1000
• LinkedIn: sunovion-pharmaceuticals-inc-

Sunovion Pharmaceuticals Inc., based in Marlborough, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapies that address critical patient needs. Founded in 2010, Sunovion focuses on drug discovery, development, and commercialization across several therapeutic areas, including psychiatry, neurology, oncology, urology, women's health, and rare diseases. The company aims to provide effective treatments for healthcare providers and patients alike. As a subsidiary of Sumitomo Pharma Co., Ltd., Sunovion benefits from a global network and resources, enhancing its ability to deliver impactful solutions in the healthcare market. Their commitment to addressing unmet medical needs is evident in their active pipeline and ongoing clinical trials, which reflect their dedication to improving patient outcomes.

14. MSD Switzerland

• Website: msd.ch
• Ownership type: Private
• Headquarters: Lucerne, Lucerne, Switzerland
• Employee distribution: Switzerland 96%, Germany 4%
• Founded year: 1963
• Headcount: 1001-5000
• LinkedIn: msdswitzerland

MSD Merck Sharp & Dohme AG, based in Lucerne, Switzerland, is a biopharmaceutical company established in 1963. The company is dedicated to the research and development of innovative medications and vaccines aimed at tackling significant health issues. MSD Switzerland operates primarily in key therapeutic areas such as oncology, infectious diseases, and diabetes, providing essential treatments that improve patient outcomes. The company is actively involved in clinical research, coordinating numerous studies across Switzerland, which underscores its commitment to advancing medical science. MSD also emphasizes corporate responsibility, engaging in initiatives that enhance healthcare access and support local health projects. With a workforce of around 527 employees, MSD Switzerland plays a vital role in the biopharmaceutical landscape, contributing to both local and global health advancements.

15. MSD Sharp & Dohme GmbH

• Website: msd.de
• Ownership type: Private
• Headquarters: Amt Neuhaus, Lower Saxony, Germany
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn: msd-sharp-%26-dohme-gmbh

MSD Sharp & Dohme GmbH, a subsidiary of Merck & Co., Inc., is a pharmaceutical company based in Amt Neuhaus, Lower Saxony, Germany. Founded in 2001, the company specializes in the research, development, and manufacturing of a wide range of medications and vaccines. MSD is particularly focused on addressing health challenges in oncology and infectious diseases, striving to enhance global health outcomes through innovative solutions. The company serves healthcare providers, hospitals, and patients, emphasizing the importance of accessible healthcare. MSD is also involved in clinical research, contributing to the advancement of medical knowledge and treatment options. With a workforce of approximately 2,438 employees, MSD operates as a private entity and is recognized as one of the prominent pharmaceutical manufacturers in Germany.

16. Sanofi Belgium

• Website: sanofi.be
• Ownership type: Private
• Headquarters: Machelen, Flanders, Belgium
• Employee distribution: Belgium 99%
• Founded year: 2004
• Headcount: 501-1000
• LinkedIn: sanofi-belgium

Sanofi Belgium, established in 2004 and located in Machelen, Flanders, is a private pharmaceutical company that plays a crucial role in the biopharmaceutical industry. With approximately 1,600 employees across four sites in Belgium, Sanofi Belgium is involved in the entire pharmaceutical process, from research and development to the commercialization and distribution of medicines. The company is particularly focused on innovative therapies for chronic and rare diseases, showcasing a strong commitment to improving health outcomes. Their Geel facility is notable for producing therapeutic proteins through advanced cell culture techniques, while the Ghent site is dedicated to research and development of NANOBODY® technology, a novel class of therapeutic proteins. Sanofi Belgium's ongoing investments, including a recent €120 million commitment to enhance biopharmaceutical production, reflect their dedication to advancing healthcare solutions and their significant contribution to the Belgian pharmaceutical landscape.

17. Adimab

• Website: adimab.com
• Ownership type: Venture Capital
• Headquarters: Lebanon, New Hampshire, United States (USA)
• Employee distribution: United States (USA) 96%, Lebanon 4%
• Latest funding: January 2020
• Founded year: 2007
• Headcount: 51-200
• LinkedIn: adimab-llc

Adimab, founded in 2007 and based in Lebanon, New Hampshire, is a biotechnology company focused on biologics discovery and engineering. The company has developed a proprietary yeast-based platform that enables the generation of therapeutic antibodies and multispecifics. Over its 15 years of operation, Adimab has collaborated with over 115 partners, including major pharmaceutical companies and biotech firms, to create more than 500 therapeutic programs. Their work has led to over 70 clinical programs originating from their platform, showcasing their capability in translating scientific hypotheses into viable therapeutic solutions. Adimab's commitment to innovation and collaboration positions it as a notable entity in the biopharmaceutical industry.

18. Acceleron Pharma

• Website: acceleronpharma.com
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 94%, Canada 6%
• Latest funding: $11.5B, September 2021
• Founded year: 2003
• Headcount: 201-500
• LinkedIn: acceleron-pharma

Acceleron Pharma, founded in 2003 and based in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapies for serious diseases. The company specializes in hematology and pulmonary medicine, focusing on conditions that often lack effective treatment options. Acceleron is known for its commitment to research and development, with a robust pipeline that includes therapies for pulmonary arterial hypertension and other blood disorders. The company has received substantial funding, with a notable amount reported in 2021, which underscores investor confidence in its potential to deliver impactful treatments. Acceleron's mission is to transform the lives of patients through the advancement of its therapeutic candidates, reflecting a strong alignment with the needs of the biopharmaceutical market.

19. Nimbus Therapeutics

• Website: nimbustx.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $210.0M, September 2023
• Founded year: 2009
• Headcount: 51-200
• LinkedIn: nimbus-therapeutics

Nimbus Therapeutics, founded in 2009 and based in Boston, Massachusetts, is a biotechnology firm dedicated to the discovery and development of small molecule therapeutics. The company specializes in addressing complex diseases, particularly in the fields of immunology, oncology, and metabolism. By utilizing advanced drug discovery techniques, Nimbus aims to create innovative treatment solutions that can transform patient care. Their approach involves a collaborative structure-based drug discovery engine, which leverages cutting-edge technologies such as computational chemistry and structural biology. This enables them to identify and target fundamental drivers of disease that have been challenging for other companies to address. With a workforce of around 110 employees, Nimbus Therapeutics has established itself as a key player in the biopharmaceutical industry, attracting significant investment, including a recent funding round of $210 million in September 2023.

20. MSD Animal Health Technology Labs

• Website: jobs.msd.com
• Ownership type: Private
• Headquarters: Netanya, Center, Israel
• Employee distribution: Israel 73%, France 8%, United Kingdom (UK) 7%, Other 12%
• Founded year: 1948
• Headcount: 201-500
• LinkedIn: antelliq-innovation-center

MSD Animal Health Technology Labs, based in Netanya, Israel, is a private biopharmaceutical company that specializes in the development of medicines and vaccines. Founded in 1948, the company operates under the MSD brand outside of the United States, where it is known as Merck & Co., Inc. MSD focuses on various therapeutic areas, including oncology and infectious diseases, and is dedicated to providing innovative solutions to healthcare providers and patients globally. The company places a strong emphasis on research and development, striving to tackle significant health challenges. With a workforce of approximately 345 employees, MSD is actively involved in advancing animal health, contributing to the overall well-being of both animals and humans through its scientific endeavors.

21. MedImmune

• Website: medimmune.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 78%, United Kingdom (UK) 18%, Other 4%
• Latest funding: $15.6B, April 2007
• Founded year: 1987
• Headcount: 1001-5000
• LinkedIn: medimmune

MedImmune, founded in 1987 and based in Gaithersburg, Maryland, is a biopharmaceutical company that operates as a subsidiary of AstraZeneca. The company specializes in the research and development of innovative medicines across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases. MedImmune is committed to improving health outcomes through its extensive pipeline of products. With a workforce of approximately 960 employees, the company plays a significant role in advancing biopharmaceutical science. MedImmune's focus on sustainability and patient-centered care aligns with current industry trends, making it a relevant player in the biopharmaceutical field.

22. Alzheon, Inc. | Preserving Future Memories

• Website: alzheon.com
• Ownership type: Venture Capital
• Headquarters: Framingham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 93%, Czech Republic 7%
• Latest funding: Series E-K, $100.0M, June 2024
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: alzheon

Alzheon, Inc. is a biotechnology firm based in Framingham, Massachusetts, founded in 2013. The company is dedicated to developing innovative treatments for Alzheimer's disease, focusing on valiltramiprosate (ALZ-801), which is currently undergoing Phase 3 clinical trials. This investigational oral treatment aims to slow disease progression, particularly in patients with the APOE4/4 genotype, who are at higher risk for Alzheimer's. Alzheon has engaged in extensive research and development, supported by significant funding, including a recent $100 million investment. Their work is underscored by a commitment to precision medicine, targeting high-risk patients and leveraging a strong safety profile from previous studies. Alzheon is also backed by a prominent scientific advisory board and has received grants from the National Institute on Aging to support their clinical trials, highlighting their active involvement in the biopharmaceutical industry.

23. Blau Farmacêutica

• Website: blau.com.br
• Ownership type: Private
• Headquarters: Cotia, Sao Paulo, Brazil
• Founded year: 1987
• Headcount: 1001-5000
• LinkedIn: blausiegel

Blau Farmacêutica, based in Cotia, São Paulo, Brazil, is a private pharmaceutical company that specializes in high-complexity medications and biotechnology solutions. Established in 1987, the company has grown to employ around 1,000 individuals and operates multiple manufacturing facilities. Blau focuses on providing innovative therapies that enhance patient care while minimizing treatment side effects. Its product portfolio includes medications for various medical fields such as oncology, hematology, immunology, and anesthesiology. The company serves hospitals and healthcare providers across Latin America and the United States, demonstrating its commitment to expanding access to high-quality healthcare solutions. Blau is also involved in research and development, emphasizing its role in advancing biopharmaceutical technologies. The company has received several awards and recognitions for its contributions to the industry, reflecting its dedication to quality and innovation.

24. PlantForm Corporation

• Website: plantformcorp.com
• Ownership type: Venture Capital
• Headquarters: Toronto, Ontario, Canada
• Employee distribution: Canada 91%, Brazil 9%
• Latest funding: Other (Grant), $25,000, February 2018
• Founded year: 2008
• Headcount: 11-50
• LinkedIn: plantform-corporation

PlantForm Corporation, based in Toronto, Ontario, is a biopharmaceutical company founded in 2008. The company focuses on the rapid development and production of specialty antibody and protein drugs through its proprietary _vivo_ XPRESS® technology platform. This plant-based system allows for efficient and cost-effective production of biologic drugs, catering to pharmaceutical companies and research institutions. PlantForm's pipeline includes biosimilar versions of prominent drugs such as pembrolizumab (Keytruda®) and ranibizumab (Lucentis®), as well as medical countermeasures for threats like ricin and sarin. The company has also engaged in partnerships for research and development, notably with Bio-Manguinhos in Brazil for the biosimilar pembrolizumab. In 2018, PlantForm received a grant of $25,000, which reflects ongoing support for its innovative projects. With a small team of 22 employees, PlantForm is committed to advancing biopharmaceutical solutions that improve patient outcomes and address critical health challenges.

25. Pooyesh Darou Biopharmaceutical Co.

• Website: pooyeshdarou.com
• Ownership type: Private
• Headquarters: Tehran, Tehran, Iran
• Employee distribution: Iran 100%
• Founded year: 1997
• Headcount: 201-500
• LinkedIn: pooyesh-darou-biopharmaceutical-co

Pooyesh Darou Biopharmaceutical Co., based in Tehran, Iran, has been a significant player in the biopharmaceutical industry since its inception in 1997. The company specializes in the production of recombinant biopharmaceuticals, focusing on therapeutic proteins that cater to various medical needs. With a robust portfolio that includes products like PDpoetin and Pegaferon, Pooyesh Darou has made strides in addressing critical health issues in the region. The company operates under stringent quality control measures, ensuring compliance with both national and international standards. Their facilities are equipped for the production of both active pharmaceutical ingredients (APIs) and finished products, showcasing their comprehensive capabilities in biopharmaceutical manufacturing. Collaborations with esteemed institutions like the International Center for Genetic Engineering and Biotechnology (ICGEB) further enhance their research and development efforts, positioning them as a key contributor to the biopharmaceutical landscape in Iran and beyond.

26. Eisai US

• Website: us.eisai.com
• Ownership type: Private
• Headquarters: Nutley, New Jersey, United States (USA)
• Employee distribution: United States (USA) 89%, Other 11%
• Founded year: 1995
• Headcount: 1001-5000
• LinkedIn: eisai

Eisai US, based in Nutley, New Jersey, is a pharmaceutical company that specializes in creating innovative treatments primarily in the fields of oncology and neurology. Founded in 1995, the company operates with a workforce of approximately 2,955 employees. Eisai US is dedicated to addressing the needs of patients and healthcare providers through its extensive product offerings and active participation in clinical trials. Their mission centers around human health care, which reflects their commitment to improving patient outcomes and supporting community health initiatives. Eisai US has developed notable products such as LENVIMA® for cancer treatment and LEQEMBI® for Alzheimer's disease, showcasing their focus on high-need medical areas. The company also engages in various patient support programs, further solidifying its role in the biopharmaceutical industry.

Biopharmaceutical Companies Insights: Key Companies

Want to Find More Biopharmaceutical Companies Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!